Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention

Neuropsychopharmacology

Volumn 40, Issue 3, 2015, Pages 688-700

  Bowers, Mallory E ^a   Ressler, Kerry J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; RIMONABANT; AMIDASE; BENZAMIDE DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; FATTY-ACID AMIDE HYDROLASE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BASOLATERAL AMYGDALA; CELL BODY; CONTROLLED STUDY; EMOTIONALITY; ENZYME DEGRADATION; FEAR; GENOTYPE; LOCOMOTION; MALE; MAZE TEST; MEMORY; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OPEN FIELD TEST; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REINFORCEMENT; SHOCK; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ASSOCIATION; CONDITIONING; DOSE RESPONSE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; PHYSIOLOGY;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; CHOLECYSTOKININ; CONDITIONING (PSYCHOLOGY); CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; FEAR; MALE; MICE; MICE, KNOCKOUT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CHOLECYSTOKININ B;

EID: 84922073900     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.225     Document Type: Article

References (97)

1. Abramov U, Raud S, Innos J, Lasner H, Kurrikoff K, Turna T et al (2008). Different housing conditions alter the behavioural phenotype of CCK(2) receptor-deficient mice. Behav Brain Res 193: pp 108-116.
2. Alen F, Ramirez-Lopez MT, Gomez de Heras R, Rodriguez de Fonseca F, Orio L (2013). Cannabinoid receptors and cholecystokinin in feeding inhibition. Vitam Horm 92: pp 165-196.
3. Areda T, Raud S, Philips MA, Innos J, Matsui T, Koks S et al (2006). Cat odour exposure decreases exploratory activity and alters neuropeptide gene expression in CCK(2) receptor deficient mice, but not in their wild-type littermates. Behav Brain Res 169: pp 212-219.
4. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G (2003). Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10: pp 116-128.
5. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W et al (2004). Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24: pp 9953-9961.
6. Beinfeld MC, Connolly K (2001). Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci Lett 301: pp 69-71.
7. Biro E, Sarnyai Z, Penke B, Szabo G, Telegdy G (1993). Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology 57: pp 340-345.
8. Bowers ME, Choi DC, Ressler KJ (2012). Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behav 107: pp 699-710.
9. Bradwejn J, Koszycki D, Meterissian G (1990). Cholecystokinintetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35: pp 83-85.
10. Bradwejn J, Koszycki D, Shriqui C (1991). Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48: pp 603-610.
11. Camp M, Norcross M, Whittle N, Feyder M, D'Hanis W, Yilmazer-Hanke D et al (2009). Impaired Pavlovian fear extinction is a common phenotype across genetic lineages of the 129 inbred mouse strain. Genes Brain Behav 8: pp 744-752.
12. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005). Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30: pp 516-524.
13. Chhatwal JP, Gutman AR, Maguschak KA, Bowser ME, Yang Y, Davis M et al (2009). Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 34: pp 509-521.
14. Chung L, Moore SD (2007). Cholecystokinin enhances GABAergic inhibitory transmission in basolateral amygdala. Neuropeptides 41: pp 453-463.
15. Chung L, Moore SD (2009a). Neuropeptides modulate compound postsynaptic potentials in basolateral amygdala. Neuroscience 164: pp 1389-1397.
16. Chung L, Moore SD (2009b). Cholecystokinin excites interneurons in rat basolateral amygdala. J Neurophysiol 102: pp 272-284.
17. Compton DR, Aceto MD, Lowe J, Martin BR (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277: pp 586-594.
18. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: pp 83-87.
19. Davis M (1992). The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15: pp 353-375.
20. de Montigny C (1989). Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46: pp 511-517.
21. Dietl MM, Palacios JM (1989). The distribution of cholecystokinin receptors in the vertebrate brain: species differences studied by receptor autoradiography. J Chem Neuroanat 2: pp 149-161.
22. Fanselow MS, LeDoux JE (1999). Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. Neuron 23: pp 229-232.
23. Foldy C, Lee SY, Szabadics J, Neu A, Soltesz I (2007). Cell typespecific gating of perisomatic inhibition by cholecystokinin. Nat Neurosci 10: pp 1128-1130.
24. Frankland PW, Josselyn SA, Bradwejn J, Vaccarino FJ, Yeomans JS (1996). Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Brain Res 733: pp 129-132.
25. Frankland PW, Josselyn SA, Bradwejn J, Vaccarino FJ, Yeomans JS (1997). Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci 17: pp 1838-1847.
26. Fraser GA (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 15: pp 84-88.
27. Ganon-Elazar E, Akirav I (2013). Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit. Psychoneuroendocrinology 38: pp 1675-1687.
28. Griebel G, Perrault G, Sanger DJ (1997). CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav Pharmacol 8: pp 549-560.
29. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B et al (2013). Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18: pp 813-823.
30. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I et al (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: pp 3239-3249.
31. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F et al (2009). Divergent effects of genetic variation in endocannabinoid signaling on human threat-and reward-related brain function. Biol Psychiatry 66: pp 9-16.
32. Hefner K, Whittle N, Juhasz J, Norcross M, Karlsson RM, Saksida LM et al (2008). Impaired fear extinction learning and corticoamygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 28: pp 8074-8085.
33. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: pp. 1932-1936.
34. Hernandez-Gomez AM, Aguilar-Roblero R, Perez de la Mora M (2002). Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids 23: pp 283-290.
35. Hill DR, Campbell NJ, Shaw TM, Woodruff GN (1987). Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7: pp 2967-2976.
36. Johnson NJ, Rodgers RJ (1996). Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plusmaze test of anxiety in mice. Psychopharmacology (Berl) 124: pp 355-364.
37. Joseph A, Tang M, Mamiya T, Chen Q, Yang LL, Jiao J et al (2013). Temporal association of elevated cholecystokininergic tone and adolescent trauma is critical for posttraumatic stress disorderlike behavior in adult mice. Proc Natl Acad Sci USA 110: pp 6589-6594.
38. Josselyn SA, Frankland PW, Petrisano S, Bush DE, Yeomans JS, Vaccarino FJ (1995). The CCKB antagonist, L-365 260, attenuates fear-potentiated startle. Peptides 16: pp 1313-1315.
39. Kamprath K, Romo-Parra H, Haring M, Gaburro S, Doengi M, Lutz B et al (2011). Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala. Neuropsychopharmacology 36: pp 652-663.
40. Karson MA, Whittington KC, Alger BE (2008). Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others. Neuropharmacology 54: pp 117-128.
41. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N et al (2001). Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21: pp 9506-9518.
42. Kellner M, Yassouridis A, Jahn H, Wiedemann K (1997). Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology (Berl) 133: pp 55-61.
43. Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F et al (2000). Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biol Psychiatry 47: pp 107-111.
44. Kuhnert S, Meyer C, Koch M (2013). Involvement of cannabinoid receptors in the amygdala and prefrontal cortex of rats in fear learning, consolidation, retrieval and extinction. Behav Brain Res 250: pp 274-284.
45. Kuwahara T, Kudoh T, Nakano A, Yoshizaki H, Takamiya M, Nagase H et al (1993). Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett 158: pp 1-4.
46. Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M et al (1997). Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112: pp 280-286.
47. Larsson LI, Rehfeld JF (1979). Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res 165: pp 201-218.
48. Laviolette SR, Grace AA (2006). Cannabinoids Potentiate Emotional Learning Plasticity in Neurons of the Medial Prefrontal Cortex through Basolateral Amygdala Inputs. J Neurosci 26: pp 6458-6468.
49. LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: pp 155-184.
50. Lee SH, Soltesz I (2011). Requirement for CB1 but not GABAB receptors in the cholecystokinin mediated inhibition of GABA release from cholecystokinin expressing basket cells. J Physiol 589(Pt 4): pp 891-902.
51. Lee SY, Foldy C, Szabadics J, Soltesz I (2011). Cell-type-specific CCK2 receptor signaling underlies the cholecystokinin-mediated selective excitation of hippocampal parvalbumin-positive fastspiking basket cells. J Neurosci 31: pp 10993-11002.
52. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A et al (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: pp 168-176.
53. Lin HC, Mao SC, Chen PS, Gean PW (2008). Chronic cannabinoid administration in vivo compromises extinction of fear memory. Learn Mem 15: pp 876-884.
54. Lin HC, Mao SC, Su CL, Gean PW (2009). The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex 19: pp 165-175.
55. Lin QS, Yang Q, Liu DD, Sun Z, Dang H, Liang J et al (2011). Hippocampal endocannabinoids play an important role in induction of long-term potentiation and regulation of contextual fear memory formation. Brain Res Bull 86: pp 139-145.
56. Manwell LA, Satvat E, Lang ST, Allen CP, Leri F, Parker LA (2009). FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav 94: pp 154-162.
57. Maren S, Fanselow MS (1996). The amygdala and fear conditioning: has the nut been cracked? Neuron 16: pp 237-240.
58. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: pp 530-534.
59. Mascagni F, McDonald AJ (2003). Immunohistochemical characterization of cholecystokinin containing neurons in the rat basolateral amygdala. Brain Res 976: pp 171-184.
60. Matto V, Harro J, Allikmets L (1997). The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology 36: pp 389-396.
61. McDonald AJ, Mascagni F (2001). Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 107: pp 641-652.
62. McDonald AJ, Mascagni F, Mania I, Rainnie DG (2005). Evidence for a perisomatic innervation of parvalbumin-containing interneurons by individual pyramidal cells in the basolateral amygdala. Brain Res 1035: pp 32-40.
63. Mechoulam R, Parker LA (2013). The endocannabinoid system and the brain. Annu Rev Psychol 64: pp 21-47.
64. Meis S, Munsch T, Sosulina L, Pape HC (2007). Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to cholecystokinin are mediated by a transient receptor potential-like current. Mol Cell Neurosci 35: pp 356-367.
65. Mellman TA, Davis GC (1985). Combat-related flashbacks in posttraumatic stress disorder: phenomenology and similarity to panic attacks. J Clin Psychiatry 46: pp 379-382.
66. Mercer LD, Beart PM (2004). Immunolocalization of CCK1R in rat brain using a new anti-peptide antibody. Neurosci Lett 359: pp 109-113.
67. Morisset J, Julien S, Laine J (2003). Localization of cholecystokinin receptor subtypes in the endocine pancreas. J Histochem Cytochem 51: pp 1501-1513.
68. Muller J, Corodimas KP, Fridel Z, LeDoux JE (1997). Functional inactivation of the lateral and basal nuclei of the amygdala by muscimol infusion prevents fear conditioning to an explicit conditioned stimulus and to contextual stimuli. Behav Neurosci 111: pp 683-691.
69. Muller JF, Mascagni F, McDonald AJ (2005). Coupled networks of parvalbumin-immunoreactive interneurons in the rat basolateral amygdala. J Neurosci 25: pp 7366-7376.
70. Myers KM, Davis M (2007). Mechanisms of fear extinction. Mol Psychiatry 12: pp 120-150.
71. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A et al (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18: pp 1034-1040.
72. Orio L, Crespo I, Lopez-Moreno JA, Reyes-Cabello C, Rodriguez de Fonseca F, Gomez de Heras R (2011). Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol Biochem Behav 98: pp 220-226.
73. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: pp 129-180.
74. Plendl W, Wotjak CT (2010). Dissociation of within-and between-session extinction of conditioned fear. J Neurosci 30: pp 4990-4998.
75. Quirk GJ, Repa C, LeDoux JE (1995). Fear conditioning enhances short-latency auditory responses of lateral amygdala neurons: parallel recordings in the freely behaving rat. Neuron 15: pp 1029-1039.
76. Quirk GJ, Likhtik E, Pelletier JG, Pare D (2003). Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. J Neurosci 23: pp 8800-8807.
77. Rasmussen K, Helton DR, Berger JE, Scearce E (1993). The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. Neuroreport 5: pp 154-156.
78. Raud S, Innos J, Abramov U, Reimets A, Koks S, Soosaar A et al (2005). Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 181: pp 347-357.
79. Reich CG, Mohammadi MH, Alger BE (2008). Endocannabinoid modulation of fear responses: learning and state-dependent performance effects. J Psychopharmacol 22: pp 769-777.
80. Revel L, Mennuni L, Garofalo P, Makovec F (1998). CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 9: pp 183-194.
81. Richard D, Guesdon B, Timofeeva E (2009). The brain endocannabinoid system in the regulation of energy balance. Best Pract Res Clin Endocrinol Metab 23: pp 17-32.
82. Riebe CJ, Pamplona FA, Kamprath K, Wotjak CT (2012). Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 204: pp 159-185.
83. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 9: pp 1526-1533.
84. Rooman I, Lardon J, Flamez D, Schuit F, Bouwens L (2001). Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas. Gastroenterology 121: pp 940-949.
85. Ryan SJ, Ehrlich DE, Jasnow AM, Daftary S, Madsen TE, Rainnie DG (2012). Spike-timing precision and neuronal synchrony are enhanced by an interaction between synaptic inhibition and membrane oscillations in the amygdala. PLoS One 7: pp e35320.
86. Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: pp 565-572.
87. Sekiguchi R, Moroji T (1986). A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea pig brain. Brain Res 399: pp 271-281.
88. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: pp 332-340.
89. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: pp 393-411.
90. Tsutsumi T, Akiyoshi J, Isogawa K, Kohno Y, Hikichi T, Nagayama H (1999). Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158. Neuropeptides 33: pp 483-486.
91. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP et al (2003). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138: pp 544-553.
92. Uriguen L, Garcia-Gutierrez MS, Manzanares J (2011). Decreased GABAA and GABAB receptor functional activity in cannabinoid CB1 receptor knockout mice. J Psychopharmacol 25: pp 105-110.
93. Vanderhaeghen JJ, Signeau JC, Gepts W (1975). New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257: pp 604-605.
94. Voikar V, Polus A, Vasar E, Rauvala H (2005). Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes Brain Behav 4: pp 240-252.
95. Woodruff AR, Sah P (2007). Inhibition and synchronization of basal amygdala principal neuron spiking by parvalbuminpositive interneurons. J Neurophysiol 98: pp 2956-2961.
96. Yoshida T, Uchigashima M, Yamasaki M, Katona I, Yamazaki M, Sakimura K et al (2011). Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus. Proc Natl Acad Sci USA 108: pp 3059-3064.
97. Zarbin MA, Innis RB, Wamsley JK, Snyder SH, Kuhar MJ (1983). Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 3: pp 877-906.